MedTrace Logo

Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure

NCT01692119 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2021-04-22

Study results available
· View outcomes & findings →

Summary

The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety endpoint) in elderly patients with chronic heart failure. The intervention, consisting of regular contacts with the local pharmacy and weekly dosing aids, aims to improve medication adherence and management.

Conditions

Interventions

BEHAVIORAL

Regular, pharmacy based intervention

Regular, pharmacy-based intervention conducted in cooperation with the treating physician: * Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan. * Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician.

Sponsors & Collaborators

  • Universität des Saarlandes

    collaborator OTHER

  • Federal Union of German Associations of Pharmacists

    lead OTHER

Principal Investigators

  • Martin Schulz, Prof. PhD · Federal Union of German Associations of Pharmacists

  • Ulrich Laufs, Prof. MD · Universitätsklinikum Leipzig

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2018-06-30
Completion
2019-03-31

Countries

  • Germany

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692119 on ClinicalTrials.gov